News

Decision Resources: Ovarian cancer drug market to triple

BY Alaric DeArment

WALTHAM, Mass. The market for drugs to treat ovarian cancer will more than triple during the period between 2008 and 2018, according to a new report by market research firm Decision Resources.

The report found that when Roche and Chugai launch Avastin (bevacizumab) in the United States and Europe in 2011 and in Japan in 2013, it will have sales of nearly $900 million in 2018, helping to drive up the value of the market more than threefold, to $1.5 billion, compared with $449 million in 2008.

The firm said that despite the low incidence of ovarian cancer relative to other cancers, drug-development activity for it is significant, with 11 drugs in late-stage development. For example, farletuzumab, made by Eisai and Morphotek, is expected to launch in the United States in 2014 and in Europe and Japan in 2016.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Keryx’s cancer drug gets fast-track designation from FDA

BY Alaric DeArment

NEW YORK The Food and Drug Administration has granted fast-track review to an investigational drug by Keryx Biopharmaceuticals for cancer, Keryx announced Monday.

The FDA granted the status to KRX-0401 (perifosine), which prevents activation of a protein in an enzyme related to advanced colorectal cancer. The FDA Fast Track program is designed to help companies develop drugs that treat serious or life-threatening conditions and that are able to address unmet medical needs.

“We believe that this fast-track designation adds substantial value to perifosine’s development in refractory, advanced colorectal cancer,” Keryx CEO Ron Bentsur said in a statement.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

CVS Caremark’s charitable arm aids Rhode Island flood relief

BY Antoinette Alexander

WOONSOCKET, R.I. The CVS Caremark Charitable Trust announced on Monday that it is donating $100,000 to the American Red Cross to support flood relief efforts across Rhode Island.

“This week’s floods made a devastating impact on Rhode Island and we want to do everything we can to help the state and its residents recover as quickly as possible,” stated Eileen Howard Dunn, VP of the CVS Caremark Charitable Trust. “The CVS Caremark Charitable Trust and the American Red Cross have partnered many times over the years on disaster relief efforts and we are pleased to support the critical aid they are providing to flood victims in Rhode Island.”

The CVS Caremark Charitable Trust is a private foundation created by CVS Caremark. The mission is to provide funding for programs serving children with disabilities as well as nonprofits that provide healthcare services to the uninsured and medically at-risk populations.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES